Jiangsu Hengrui Pharmaceuticals Co.,Ltd.(600276),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

600276 Jiangsu Hengrui Pharmaceuticals Co.,Ltd.

Closed 05-15 15:00:00

53.99

-0.33

-0.61%

High55.66	Low53.75	Vol76.60M
Open54.08	D1 Closing54.32	Amplitude3.52%
Mkt Cap358.33B	Tradable Cap344.40B	Total Shares6.64B
T/O4.17B	T/O Rate1.20%	Tradable Shares6.38B
P/B5.63	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"600276","market":"SH","secType":"STK","nameCN":"Jiangsu Hengrui Pharmaceuticals Co.,Ltd.","latestPrice":53.99,"timestamp":1778828400000,"preClose":54.32,"halted":0,"volume":76598895,"delay":0,"changeRate":-0.0061,"floatShares":6379000000,"shares":6637000000,"eps":1.2233,"marketStatus":"Closed","change":-0.33,"latestTime":"05-15 15:00:00","open":54.08,"high":55.66,"low":53.75,"amount":4174000000,"amplitude":0.0352,"askPrice":54,"askSize":2922,"bidPrice":53.99,"bidSize":30,"shortable":0,"etf":0,"ttmEps":1.2233,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1779067800000},"marketStatusCode":5,"adr":0,"adjPreClose":54.32,"symbolType":"stock","openAndCloseTimeList":[[1778808600000,1778815800000],[1778821200000,1778828400000]],"highLimit":59.75,"lowLimit":48.89,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":6637199874,"isCdr":false,"pbRate":5.63,"roa":"--","peRate":44.134718,"roe":"4.15%","epsLYR":1.19,"committee":-0.50149,"marketValue":358342000000,"turnoverRate":0.012,"status":1,"nextConnectDate":"Northbound have stopped. The next trading day is UTC+8 2026-05-18.","hkstockBrief":{"symbol":"01276","market":"HK","secType":"STK","nameCN":"HENGRUI PHARMA","latestPrice":65.75,"timestamp":1778832545004,"preClose":66.4,"halted":0,"volume":3735083,"delay":0,"premium":"+5.89"},"floatMarketCap":344402000000},"requestUrl":"/m/hq/s/600276/tweets","defaultTab":"tweets","newsList":[{"id":"2635882430","title":"Hengrui Pharmaceuticals' Development Capabilities Undervalued -- Market Talk","url":"https://stock-news.laohu8.com/highlight/detail?id=2635882430","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635882430?lang=en_us&edition=fundamental","pubTime":"2026-05-15 18:09","pubTimestamp":1778839740,"startTime":"0","endTime":"0","summary":"1009 GMT - Hengrui Pharmaceuticals' research and development and business development capabilities remain undervalued, HSBC researchers say in a note. They highlight the value of Hengrui's recent $15.2 billion deal with Bristol Myer-Squibb exceeded its deal with GSK last year, reflecting broad recognition of Hengrui's R&D capabilities and efficiency. The drugmaker's strong clinical pipeline and efficient drug discovery platform should support a recurring business development model and create additional collaboration opportunities. HSBC maintains its 2026 results forecasts but raises its 2027-2028 revenue and net profit estimates as well as its R&D costs projections. Industry-wise, Chinese drugmakers are likely to continue securing business development deals with multinational pharmaceutical companies despite geopolitical risks, supported by high efficiency, lower R&D costs and improving data transparency. Hengrui's H-shares last closed at HK$65.75. ","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0028","LU0976567544.SGD","LU2148510915.USD","LU0405327494.USD","LU2495084118.USD","600276","BK0012","HSBC","LU0128525689.USD","LU1997245094.SGD","BK0196","BK4585","BK0188","LU0496365809.HKD","LU0310800965.SGD","LU0052756011.USD","LU0211326755.USD","LU1781817850.SGD","LU2289578879.USD","HSBH","LU1146622755.USD","LU1255011170.USD","LU1267930227.SGD","BK0183","LU2580892862.HKD","LU2580892789.USD","BK4588","LU1820825898.SGD","LU1064130708.USD","LU2328871848.SGD","LU1997245177.USD","LU2488822045.USD","BK4521","BK0060","LU1064131003.USD","LU1328615791.USD","LU1969619763.USD","LU2097828474.EUR","LU2097828714.EUR","LU0405327148.USD","LU2097828631.EUR","LU2097828805.USD","LU2097828557.USD","LU1655091616.SGD","LU1580142542.USD","LU0211326839.USD","LU2236285917.USD","LU1997244956.HKD","BK4207","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1137880618","title":"HENGRUI PHARMA's Subsidiary Gains Approval for Clinical Trials of SHR-3079 Injection","url":"https://stock-news.laohu8.com/highlight/detail?id=1137880618","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1137880618?lang=en_us&edition=fundamental","pubTime":"2026-05-14 16:48","pubTimestamp":1778748516,"startTime":"0","endTime":"0","summary":"HENGRUI PHARMA announced that its subsidiary, Suzhou Shengdiya Biopharmaceutical Co., Ltd., recently received a \"Drug Clinical Trial Approval Notice\" for SHR-3079 injection from the National Medical...","market":"fut","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2488822045.USD","01276","BK0196","LU0405327494.USD","LU2289578879.USD","BK0183","LU1023057109.AUD","LU2097828805.USD","BK0188","LU0359201612.USD","BK0028","600276","LU1997245094.SGD","LU1997244956.HKD","BK1191","LU2097828631.EUR","LU2495084118.USD","LU2328871848.SGD","LU1064130708.USD","LU2543165471.USD","LU2097828474.EUR","LU1781817850.SGD","LU2580892862.HKD","LU2148510915.USD","LU1255011170.USD","LU1328615791.USD","LU2097828557.USD","LU1820825898.SGD","LU2097828714.EUR","BK0239","LU1146622755.USD","LU1580142542.USD","BK0060","LU2580892789.USD","LU1969619763.USD","LU1655091616.SGD","LU1997245177.USD","LU0359201885.HKD","LU0359202008.SGD","LU1064131003.USD","BK0012","LU0405327148.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1100038164","title":"Morgan Stanley: Hengrui Pharma's $15.2 Billion Partnership with BMS to Accelerate Global Expansion","url":"https://stock-news.laohu8.com/highlight/detail?id=1100038164","media":"Stock News","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1100038164?lang=en_us&edition=fundamental","pubTime":"2026-05-13 11:00","pubTimestamp":1778641225,"startTime":"0","endTime":"0","summary":"Morgan Stanley has issued a research report highlighting a global strategic collaboration between Hengrui Pharma and Bristol Myers Squibb, covering 13 pre-clinical assets with a total transaction...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"d8fdac8d3d9097cb034fb43ab6bd5883","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0405327494.USD","LU2148510915.USD","LU1997245094.SGD","LU2289578879.USD","LU0359201612.USD","LU1328615791.USD","BK0012","LU0359202008.SGD","LU1064131003.USD","BMS","600276","BK0028","BK1191","LU1655091616.SGD","LU2097828474.EUR","LU2328871848.SGD","LU1255011170.USD","LU2488822045.USD","LU2097828714.EUR","LU2580892789.USD","BK0196","LU1781817850.SGD","BK0188","LU2097828557.USD","BK0183","LU0405327148.USD","LU1997245177.USD","LU1064130708.USD","BK0060","LU2495084118.USD","LU1580142542.USD","BK0239","01276","LU2097828631.EUR","LU2097828805.USD","LU0359201885.HKD","LU1969619763.USD","LU1023057109.AUD","LU1997244956.HKD","LU1146622755.USD","LU2543165471.USD","LU1820825898.SGD","LU2580892862.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634121464","title":"Dow Jones Top Company Headlines at 9 AM ET: EBay Rejects GameStop's $56 Billion Takeover Proposal | Under ...","url":"https://stock-news.laohu8.com/highlight/detail?id=2634121464","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634121464?lang=en_us&edition=fundamental","pubTime":"2026-05-12 21:00","pubTimestamp":1778590800,"startTime":"0","endTime":"0","summary":"The e-commerce platform called the offer \"neither credible nor attractive\" after a rollout by GameStop CEO Ryan Cohen appeared to fizzle.Under Armour reported a fiscal fourth-quarter loss as revenue declines in North America offset international sales gains.JD.com returned to profit with better-than-expected results in the first quarter, as the Chinese e-commerce giant made progress in stemming losses in its food-delivery business.Bristol-Myers Squibb and China's Hengrui Pharma Forge Tie-Up. U.S. pharma giant Bristol-Myers Squibb has struck a partnership and licensing deal with Chinese drugmaker Hengrui, in a deal that could worth more than $15 billion.EU's Von der Leyen Floats Tighter Restrictions for Minors' Social Media Use. The European Union could present new rules to tighten restrictions on minors' use of social media platforms this summer.Nvidia Stock Drops After Report CEO Huang Is Excluded From Trump's China Trip. Sam Altman's Business Dealings Under GOP Scrutiny Ahead of Open","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"c1ee3020066801ecc9807d71c3848eaf","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BZ18W456.USD","ADNOC.AU","600276","EBAY","TCEHY","BK4585","RGTI","JD","GMEU","BMY","01024","BK4076","NVO","GME","BK4144","DJIA","IE00BMQBXF63.USD","BK4561","BK4590","NVDA","BK4588","BK4577","00700","09618","BK4581","IGME","UAA","IE00BZ18W340.USD","BAYRY","BZFD","GMEY","01276","BK4547"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1127154866","title":"Afternoon Market Surge: 600276 Hits Limit-Up in Minutes; Thousand-Yuan Stock 300308 Attracts Capital Inflows","url":"https://stock-news.laohu8.com/highlight/detail?id=1127154866","media":"Deep News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1127154866?lang=en_us&edition=fundamental","pubTime":"2026-05-12 17:11","pubTimestamp":1778577077,"startTime":"0","endTime":"0","summary":"On May 12, the A-share market experienced minor overall fluctuations, with major indices showing mixed performance. The STAR Composite Index reached another historic high, while the ChiNext Index...","market":"fut","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0077","LU2580892789.USD","SG9999011746.SGD","LU0164865239.USD","HK0000320223.HKD","LU2476274720.SGD","LU1655091616.SGD","IE00BYTNYN87.SGD","600276","LU1303224171.USD","LU1251922891.USD","SGXZ49509284.SGD","LU1328615791.USD","LU1997245177.USD","LU1997245094.SGD","LU0039217434.USD","SGXZ81163826.USD","HK0000306701.USD","LU2213484517.USD","LU0405327148.USD","LU1064131003.USD","LU2488822045.USD","LU1720050803.USD","LU1997244956.HKD","LU0871576103.HKD","LU2097828714.EUR","LU1719994722.HKD","LU1820825898.SGD","BK0183","LU1979443071.USD","LU0348827113.USD","LU1961090484.USD","BK0028","BK0012","LU0348735423.USD","LU0531971595.HKD","IE00BYQNZ168.SGD","HK0000306685.HKD","LU2097828474.EUR","LU0164939612.USD","BK0196","LU1146622755.USD","LU2495084118.USD","LU2328871848.SGD","LU2778985437.USD","LU0620787316.HKD","IE00B12V2V27.USD","LU1781817850.SGD","LU0561508036.HKD","LU2097828805.USD","LU1934453819.USD","BK0060","LU0082770016.SGD","LU1794554557.SGD","LU0417516738.SGD","LU0634319403.HKD","LU0540923850.HKD","LU2580892862.HKD","300308","BK0188","LU2399975544.HKD","HK0000320264.USD","LU0082770016.USD","LU0405327494.USD","LU0417516902.SGD","BK0239","LU1064130708.USD","LU2148510915.USD","LU2097828631.EUR","BK0070","LU2476274308.USD","LU1770034418.SGD","LU0348825331.USD","IE0034224299.USD","LU1255011170.USD","LU2289578879.USD","LU2097828557.USD","BK0167","LU1580142542.USD","BK0214","LU1969619763.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634547299","title":"Hong Kong Stocks End Lower as U.S.-Iran Talks Remain Stalled; Hengrui Pharma Jumps","url":"https://stock-news.laohu8.com/highlight/detail?id=2634547299","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634547299?lang=en_us&edition=fundamental","pubTime":"2026-05-12 16:38","pubTimestamp":1778575137,"startTime":"0","endTime":"0","summary":"Hong Kong stocks ended slightly lower on Tuesday as fading expectations for progress in U.S.-Iran negotiations and caution ahead of U.S. inflation data weighed on sentiment.The Hang Seng Index shed 0.2%, or 58.93 points, to close at 26,347.91, while the Hang Seng China Enterprises Index barely moved in negative territory to finish at 8,882.37.U.S. President Donald Trump said on Monday that a ceasefire with Iran was \"on life support\" after Tehran's response to a U.S. proposal highlighted divisions between the two sides.Tehran has called for compensation for war-related damage, an end to the U.S. naval blockade, assurances against further attacks, and the resumption of Iranian oil exports.Markets are also closely watching Trump's visit to China, which begins on Wednesday.In corporate news, Hengrui Pharmaceuticals  advanced nearly 5% in Hong Kong after signing a drug development deal with Bristol Myers Squibb worth up to $15.2 billion.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"f6f7c9f6a0174df79daf9f1dfd21f836","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK0196","BK0188","LU1997245177.USD","BK0239","LU2543165471.USD","BMY","BK0183","LU1064131003.USD","BK0060","LU1969619763.USD","LU2097828631.EUR","MHImain","LU1064130708.USD","HSI","LU2495084118.USD","600276","LU2488822045.USD","LU2148510915.USD","LU0405327148.USD","LU1781817850.SGD","LU1023057109.AUD","LU1997245094.SGD","LU2097828474.EUR","513600","HSTECH","LU2097828557.USD","LU0405327494.USD","LU1580142542.USD","LU2289578879.USD","LU2580892862.HKD","LU2097828714.EUR","LU1820825898.SGD","LU1655091616.SGD","LU2580892789.USD","LU1997244956.HKD","LU1328615791.USD","HHImain","BK0012","LU1255011170.USD","LU0359201885.HKD","01276","LU1146622755.USD","02833","LU0359201612.USD","MCHmain","BK0028","LU0359202008.SGD","LU2328871848.SGD","LU2097828805.USD","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1122537782","title":"Major Boost of RMB 100 Billion: Hengrui Pharma Sees Sharp Surge","url":"https://stock-news.laohu8.com/highlight/detail?id=1122537782","media":"Deep News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1122537782?lang=en_us&edition=fundamental","pubTime":"2026-05-12 16:31","pubTimestamp":1778574672,"startTime":"0","endTime":"0","summary":"The market experienced a slight adjustment today. Let's review the key developments. On May 12, the market traded in a narrow range with low volume throughout the day, with the three major indices...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0012","LU1146622755.USD","LU1580142542.USD","LU2495084118.USD","LU2097828631.EUR","LU2580892862.HKD","BK0196","BK0060","LU1820825898.SGD","LU2097828557.USD","LU0405327148.USD","LU2148510915.USD","LU1064130708.USD","LU1655091616.SGD","LU1997245094.SGD","LU1969619763.USD","BK0188","LU0405327494.USD","LU2289578879.USD","LU1064131003.USD","BK0239","LU1997245177.USD","LU2097828714.EUR","LU2580892789.USD","BK0183","LU2097828474.EUR","LU2328871848.SGD","BK0028","LU1255011170.USD","LU1328615791.USD","LU2488822045.USD","LU2097828805.USD","600276","LU1997244956.HKD","LU1781817850.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634429864","title":"Hengrui's Deal With Bristol Myers Squibb Should Ease Concerns Over Dealmaking Slowdown -- Market Talk","url":"https://stock-news.laohu8.com/highlight/detail?id=2634429864","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634429864?lang=en_us&edition=fundamental","pubTime":"2026-05-12 15:12","pubTimestamp":1778569920,"startTime":"0","endTime":"0","summary":"0712 GMT - The strategic partnership and licensing deals between Hengrui Pharmaceuticals and BRistol Myers Squibb should help ease investor concerns over any slowdown in Hengrui's dealmaking activity, Nomura China healthcare analyst Jialin Zhang says in a note. Zhang adds that seven months have passed since Hengrui last announced a collaboration agreement, a gap that explains the recent weakness in its share price. However, the BMS deal reaffirms its capabilities and serves as a proxy for China's biopharma innovation out-licensing, he says. \"We also believe the company set a good example regarding maintaining confidentiality about this deal until it was officially disclosed,\" he adds. Nomura maintains a buy rating and a target price of HK$87.49 on Hengrui's Hong Kong-listed stock. The H-shares are last at HK$68.80. ","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BFTCPJ56.SGD","600276","LU1571399168.USD","LU2360032135.SGD","BK0060","LU2580892789.USD","LU0321505868.SGD","IE00BJT1NW94.SGD","BK0188","BK0239","BMY","LU1580142542.USD","LU2097828714.EUR","LU1997245094.SGD","LU2580892862.HKD","LU2097828474.EUR","LU1291159041.SGD","LU1969619763.USD","LU1983299246.USD","LU1146622755.USD","LU1093756168.USD","LU1255011170.USD","LU1997245177.USD","IE00BFXG1179.USD","LU2148510915.USD","LU1781817850.SGD","LU2133065610.SGD","LU1670711123.USD","LU0882574055.USD","LU1032466523.USD","LU1074936037.SGD","LU2328871848.SGD","LU1323610961.USD","LU1670710588.SGD","BK0028","LU2289578879.USD","BK4588","LU0114720955.EUR","LU0456855351.SGD","LU1883839398.USD","LU2125154935.USD","LU2495084118.USD","LU1868837136.USD","LU0096364046.USD","BK0012","LU0306806265.USD","LU1655091616.SGD","BK4007","LU1868836757.USD","BK4581"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1118750921","title":"Massive $15.2 Billion Collaboration: Hengrui Pharma Partners with BMS to Accelerate 13 Novel Drug Programs","url":"https://stock-news.laohu8.com/highlight/detail?id=1118750921","media":"Deep News","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1118750921?lang=en_us&edition=fundamental","pubTime":"2026-05-12 14:02","pubTimestamp":1778565721,"startTime":"0","endTime":"0","summary":"Hengrui Pharma announced at midday on the 12th that it has entered into a global strategic collaboration and licensing agreement with Bristol-Myers Squibb (BMS). The partnership aims to jointly...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"d8fdac8d3d9097cb034fb43ab6bd5883","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0359202008.SGD","LU2580892789.USD","LU1820825898.SGD","LU2488822045.USD","LU2580892862.HKD","LU2097828805.USD","BK0012","LU1146622755.USD","LU2543165471.USD","LU2097828474.EUR","600276","LU1064131003.USD","LU1023057109.AUD","LU2495084118.USD","01276","BK0188","LU1655091616.SGD","LU2328871848.SGD","BK0183","LU2289578879.USD","LU2097828557.USD","LU1328615791.USD","BK1191","LU1064130708.USD","BK0028","BMS","LU2148510915.USD","LU1781817850.SGD","LU1997245177.USD","LU0359201885.HKD","LU2097828631.EUR","LU0405327494.USD","LU0359201612.USD","LU0405327148.USD","LU1580142542.USD","LU1969619763.USD","BK0239","BK0060","LU2097828714.EUR","LU1997244956.HKD","LU1255011170.USD","LU1997245094.SGD","BK0196"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1148349561","title":"HENGRUI PHARMA Shares Surge on Major Strategic Alliance with Bristol-Myers Squibb, Deal Valued Up to $15.2 Billion","url":"https://stock-news.laohu8.com/highlight/detail?id=1148349561","media":"Stock News","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1148349561?lang=en_us&edition=fundamental","pubTime":"2026-05-12 13:41","pubTimestamp":1778564473,"startTime":"0","endTime":"0","summary":"HENGRUI PHARMA (01276) experienced a sharp increase in afternoon trading, rising over 16% at its peak. As of the latest update, the stock was up 6.21%, trading at HKD 70.15 with a turnover of HKD...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"d8fdac8d3d9097cb034fb43ab6bd5883","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4559","IE00BSNM7G36.USD","LU1670711123.USD","LU1064131003.USD","LU1983299246.USD","LU1093756325.SGD","LU1997244956.HKD","IE0009355771.USD","LU0114720955.EUR","LU1997245094.SGD","LU2242652126.USD","LU2097828474.EUR","LU2097828631.EUR","IE00BJT1NW94.SGD","LU1585245621.USD","LU0096364046.USD","BK0028","LU1670711040.USD","LU0321505439.SGD","LU1989771016.USD","BK0183","LU2148510915.USD","BK4534","LU1261432733.SGD","LU2097828714.EUR","LU2360032135.SGD","LU1074936037.SGD","IE0002141913.USD","LU1023057109.AUD","LU2488822045.USD","LU1969619763.USD","LU0456855351.SGD","LU1032466523.USD","LU1820825898.SGD","BK0196","LU2328871848.SGD","LU1291159041.SGD","LU1146622755.USD","LU2125154778.USD","LU0225771236.USD","LU2242646821.SGD","BK4007","BMY","VXUS","LU1670710588.SGD","LU0321505868.SGD","LU1718418525.SGD","LU2097828557.USD","LU2097828805.USD","LU0225284248.USD","BK4532","LU2133065610.SGD","LU1670710661.SGD","LU2289578879.USD","LU2580892789.USD","LU0359201612.USD","LU0061475181.USD","IE00BJJMRZ35.SGD","LU1323610961.USD","IE00B2B36J28.USD","LU2543165471.USD","BK0060","LU1093756168.USD","LU1868836591.USD","BK4581","LU2495084118.USD","BK0012","LU0237698245.USD","BK0188","LU2125154935.USD","LU1781817850.SGD","LU1580142542.USD","LU1571399168.USD","LU0267386448.USD","LU1868836914.USD","600276","LU1655091616.SGD","LU1255011170.USD","BK4588","LU0359202008.SGD","LU1868837136.USD","LU0985481810.HKD","LU0432979614.USD","LU0359201885.HKD","LU0306807586.USD","BK1191","01276","LU1064130708.USD","LU1868836757.USD","BK4585","LU0306806265.USD","LU1328615791.USD","LU1883839398.USD","IE00BFXG1179.USD","LU0405327148.USD","LU1997245177.USD","LU1430594728.SGD","LU2580892862.HKD","LU0868494617.USD","LU0405327494.USD","BK0239","LU0882574055.USD","IE00BFTCPJ56.SGD","LU1868837300.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1130368732","title":"HENGRUI PHARMA's Hong Kong Shares Surge Over 15% in Afternoon Trading Following Strategic Alliance with BMS","url":"https://stock-news.laohu8.com/highlight/detail?id=1130368732","media":"Deep News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1130368732?lang=en_us&edition=fundamental","pubTime":"2026-05-12 13:20","pubTimestamp":1778563230,"startTime":"0","endTime":"0","summary":"HENGRUI PHARMA's Hong Kong-listed shares experienced a significant afternoon surge, climbing more than 15% and reaching an intraday high of HKD 76.75. The catalyst for the move was the company's...","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"b1f4c1fa965d76d4e78087079f689b4e","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0028","LU1023057109.AUD","LU2148510915.USD","BMS","LU0405327494.USD","01276","VXUS","LU2495084118.USD","600276","BK0012","LU1997245094.SGD","BK0196","LU0359201612.USD","LU0359201885.HKD","BK4585","BK0188","LU1781817850.SGD","LU1255011170.USD","LU1146622755.USD","BK0183","LU2580892862.HKD","LU2580892789.USD","LU0359202008.SGD","BK4588","LU1820825898.SGD","LU1064130708.USD","LU2328871848.SGD","LU1997245177.USD","LU2488822045.USD","BK0060","LU1064131003.USD","LU1328615791.USD","LU1969619763.USD","LU2097828474.EUR","LU2097828714.EUR","LU0405327148.USD","LU2097828631.EUR","LU2097828805.USD","LU2097828557.USD","LU1655091616.SGD","BK1191","LU1580142542.USD","LU2543165471.USD","LU1997244956.HKD","LU2289578879.USD","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634266078","title":"BUZZ-Jiangsu Hengrui HK shares hit near 4-month peak on Bristol-Myers Squibb tie-up","url":"https://stock-news.laohu8.com/highlight/detail?id=2634266078","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634266078?lang=en_us&edition=fundamental","pubTime":"2026-05-12 13:12","pubTimestamp":1778562755,"startTime":"0","endTime":"0","summary":"BUZZ-Jiangsu Hengrui HK shares hit near 4-month peak on Bristol-Myers Squibb tie-up** Hong Kong shares of Jiangsu Hengrui Pharmaceuticals jump 16.2% in the second rising session to HK$76.75, their highest point since January 20 ** Stock set for the biggest one-day pct gain since July 28, 2025 ** Shanghai-listed shares 600276.SS surge 8.6% to 58.1 yuan, set for the biggest one-day pct gain since April 15** China-based oncology-focused drug developer enters into collaboration and license deals with Bristol-Myers Squibb  BMY.N to advance a portfolio of 13 early-stage programs in oncology, hematology, and immunology ** BMS will pay Hengrui up to $950 million, including a $600 million upfront payment, a $175 million first anniversary payment, and a second contingent anniversary payment of $175 million in 2028** The potential milestone payments of the agreements are up to $15.2 billion** YTD, Shanghai-listed stock down 1.7%, while Hong Kong stock up 2.1%, Hang Seng Biotech Index .HSBIO up 2.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"b1f4c1fa965d76d4e78087079f689b4e","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260512:nL1N41P05A:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2242652126.USD","LU2580892862.HKD","BK4585","LU0321505868.SGD","LU1032466523.USD","LU2148510915.USD","LU1820825898.SGD","LU0456855351.SGD","IE0002141913.USD","LU1064130708.USD","LU0405327148.USD","LU1670710661.SGD","LU0225771236.USD","LU1146622755.USD","LU0432979614.USD","LU1969619763.USD","LU2133065610.SGD","LU2097828631.EUR","01276","LU2328871848.SGD","BK0012","LU1023057109.AUD","IE00BJJMRZ35.SGD","IE00BJT1NW94.SGD","IE00BFXG1179.USD","LU0405327494.USD","LU2488822045.USD","LU1585245621.USD","LU2289578879.USD","LU2580892789.USD","BK4534","LU0985481810.HKD","LU1328615791.USD","LU1655091616.SGD","LU1997245177.USD","LU1571399168.USD","LU1781817850.SGD","LU0096364046.USD","600276","BK0239","LU0225284248.USD","LU0321505439.SGD","LU0359202008.SGD","LU2125154935.USD","LU1997244956.HKD","BK1191","BMY","LU2097828474.EUR","IE00BFTCPJ56.SGD","LU1989771016.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634026567","title":"Hengrui Pharma and Bristol Myers Squibb Announce Strategic Agreements to Advance Innovative Medicines Across Oncology, Hematology, and Immunology","url":"https://stock-news.laohu8.com/highlight/detail?id=2634026567","media":"THOMSON REUTERS","labels":["event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634026567?lang=en_us&edition=fundamental","pubTime":"2026-05-12 12:27","pubTimestamp":1778560068,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"b1f4c1fa965d76d4e78087079f689b4e","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260512:nTUA96KBPR:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"event","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU2097828805.USD","BK0028","BK0239","600276","LU2097828474.EUR","LU2328871848.SGD","LU1997244956.HKD","LU1969619763.USD","LU1997245094.SGD","LU2495084118.USD","LU2097828714.EUR","LU1064130708.USD","LU1781817850.SGD","LU2580892789.USD","LU1655091616.SGD","LU2097828557.USD","LU2580892862.HKD","LU1820825898.SGD","BK0196","LU0405327148.USD","BK0183","LU0405327494.USD","BK0060","LU2289578879.USD","LU1146622755.USD","LU1328615791.USD","LU1997245177.USD","LU2097828631.EUR","BK0188","LU2148510915.USD","LU2488822045.USD","LU1064131003.USD","BK0012","LU1580142542.USD","LU1255011170.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1155645459","title":"HENGRUI PHARMA Forges Global Alliance with Bristol-Myers Squibb on Early-Stage Pipeline","url":"https://stock-news.laohu8.com/highlight/detail?id=1155645459","media":"Stock News","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1155645459?lang=en_us&edition=fundamental","pubTime":"2026-05-12 12:20","pubTimestamp":1778559630,"startTime":"0","endTime":"0","summary":"HENGRUI PHARMA (01276) has announced that Jiangsu Hengrui Pharmaceuticals Co.,Ltd. has entered into a global strategic collaboration and licensing agreement with Bristol-Myers Squibb Company (BMS)....","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"b1f4c1fa965d76d4e78087079f689b4e","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","BK4532","LU2133065610.SGD","LU2495084118.USD","LU1997244956.HKD","BK0183","BK0196","LU0405327494.USD","BK4585","LU1585245621.USD","LU1997245094.SGD","LU0405327148.USD","LU2148510915.USD","LU0225771236.USD","IE00BSNM7G36.USD","BK0028","BK0239","LU2097828714.EUR","LU1868837300.USD","LU0267386448.USD","LU1255011170.USD","LU1261432733.SGD","LU1670711123.USD","LU2097828557.USD","LU1032466523.USD","LU1023057109.AUD","LU1328615791.USD","BK1191","LU1430594728.SGD","LU1580142542.USD","IE00BJJMRZ35.SGD","LU1969619763.USD","LU2580892789.USD","IE00BFTCPJ56.SGD","LU1868836591.USD","LU1064131003.USD","IE00B2B36J28.USD","LU1571399168.USD","LU1868836914.USD","BK0060","LU2097828631.EUR","BK4534","LU0096364046.USD","BK4581","LU0456855351.SGD","LU1093756168.USD","LU2125154935.USD","LU1655091616.SGD","LU1718418525.SGD","600276","LU1291159041.SGD","LU1868837136.USD","LU2543165471.USD","BK0188","LU0432979614.USD","IE0002141913.USD","LU1064130708.USD","IE00BFXG1179.USD","LU2097828474.EUR","LU2097828805.USD","LU0306806265.USD","LU2242652126.USD","LU2125154778.USD","LU0868494617.USD","LU2360032135.SGD","LU1868836757.USD","LU0061475181.USD","01276","LU1781817850.SGD","BK4588","LU0882574055.USD","IE0009355771.USD","LU1670710661.SGD","LU0359201612.USD","LU2328871848.SGD","LU1989771016.USD","LU0114720955.EUR","LU0359202008.SGD","LU0237698245.USD","LU0985481810.HKD","LU1670711040.USD","BMY","LU1074936037.SGD","LU0359201885.HKD","LU2488822045.USD","LU0306807586.USD","LU1670710588.SGD","IE00BJT1NW94.SGD","LU2580892862.HKD","LU1323610961.USD","LU2289578879.USD","BK4559","LU1997245177.USD","LU1883839398.USD","LU0225284248.USD","LU0321505439.SGD","LU1093756325.SGD","LU2242646821.SGD","LU1983299246.USD","LU1820825898.SGD","LU0321505868.SGD","BK0012","LU1146622755.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634809265","title":"China's Jiangsu Hengrui, Bristol Myers Squibb in deal worth up to $15.2 bln","url":"https://stock-news.laohu8.com/highlight/detail?id=2634809265","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634809265?lang=en_us&edition=fundamental","pubTime":"2026-05-12 12:16","pubTimestamp":1778559415,"startTime":"0","endTime":"0","summary":"China's Jiangsu Hengrui, Bristol Myers Squibb in deal worth up to $15.2 blnMay 12  - China's Jiangsu Hengrui Pharmaceuticals 1276.HK 600276.SS said on Tuesday it has struck global strategic collaboration and licensing deal with U.S. drugmaker Bristol Myers Squibb BMY.N to develop 13 earlystage oncology, hematology and immunology programmes, with potential milestone payments of up to $15.2 billion.  ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"d8fdac8d3d9097cb034fb43ab6bd5883","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260512:nL4N41P0BH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0306806265.USD","BK4585","LU0985481810.HKD","LU1655091616.SGD","LU1323610961.USD","LU2360032135.SGD","LU0267386448.USD","BMY","IE00BFXG1179.USD","BK4559","LU0405327494.USD","LU1868837300.USD","LU2580892862.HKD","LU1718418525.SGD","600276","LU1585245621.USD","01276","LU2097828714.EUR","BK4534","LU1670710661.SGD","LU1093756168.USD","BK0183","LU1983299246.USD","LU1032466523.USD","LU1146622755.USD","LU1064131003.USD","LU2133065610.SGD","LU2242646821.SGD","LU1868837136.USD","BK0060","BK4532","LU1670711123.USD","LU0456855351.SGD","LU1064130708.USD","IE00BFTCPJ56.SGD","LU0096364046.USD","LU2242652126.USD","LU2543165471.USD","LU0061475181.USD","LU2289578879.USD","LU1781817850.SGD","LU0225284248.USD","IE00BJT1NW94.SGD","LU2097828805.USD","LU0321505439.SGD","LU1571399168.USD","LU2495084118.USD","LU0114720955.EUR","BK4007","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634632672","title":"Jiangsu Hengrui Pharmaceuticals - Potential Total Value of Agreements up to $15.2 Bln","url":"https://stock-news.laohu8.com/highlight/detail?id=2634632672","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634632672?lang=en_us&edition=fundamental","pubTime":"2026-05-12 12:01","pubTimestamp":1778558471,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"b1f4c1fa965d76d4e78087079f689b4e","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260512:nFWN41O1N1:4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU0267386448.USD","LU0321505439.SGD","LU1997245094.SGD","600276","IE00BFXG1179.USD","LU1093756325.SGD","LU2580892862.HKD","IE00BSNM7G36.USD","LU0868494617.USD","LU1291159041.SGD","LU0225771236.USD","LU1032466523.USD","LU1255011170.USD","LU1868836591.USD","LU1883839398.USD","LU0359202008.SGD","LU2242646821.SGD","LU2488822045.USD","LU1718418525.SGD","IE0002141913.USD","LU0306807586.USD","LU1261432733.SGD","LU1670711123.USD","01276","LU1146622755.USD","LU0306806265.USD","LU2097828557.USD","LU1093756168.USD","LU1670710661.SGD","BMY","BK4007","LU1868837300.USD","BK0188","LU1064130708.USD","LU2242652126.USD","BK1191","BK0239","LU1430594728.SGD","BK4581","IE00BFTCPJ56.SGD","LU2495084118.USD","LU1868837136.USD","LU0061475181.USD","IE00BJJMRZ35.SGD","LU1323610961.USD","LU1820825898.SGD","LU0096364046.USD","LU1670710588.SGD","LU1868836914.USD","LU0359201885.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634526343","title":"Jiangsu Hengrui Pharmaceuticals - Entering Into Collaboration and License Agreements With Bristol-Myers Squibb","url":"https://stock-news.laohu8.com/highlight/detail?id=2634526343","media":"THOMSON REUTERS","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634526343?lang=en_us&edition=fundamental","pubTime":"2026-05-12 12:01","pubTimestamp":1778558471,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"b1f4c1fa965d76d4e78087079f689b4e","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260512:nFWN41O1N1:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU1580142542.USD","LU2097828474.EUR","LU1820825898.SGD","BK0183","01276","LU1023057109.AUD","LU0405327148.USD","LU2148510915.USD","LU0359202008.SGD","BK0012","LU2580892862.HKD","BK0239","BK0188","LU1997244956.HKD","LU2097828714.EUR","LU1064130708.USD","LU2495084118.USD","LU0405327494.USD","LU2097828805.USD","LU1328615791.USD","LU2488822045.USD","LU2328871848.SGD","600276","LU0359201885.HKD","LU1997245177.USD","LU2580892789.USD","BK0196","LU1781817850.SGD","LU1997245094.SGD","BK0028","LU1064131003.USD","LU1255011170.USD","LU1146622755.USD","LU2097828631.EUR","LU1655091616.SGD","LU2289578879.USD","LU1969619763.USD","BK1191","LU2097828557.USD","LU2543165471.USD","BK0060","LU0359201612.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634474263","title":"Jiangsu Hengrui Pharmaceuticals - Bms Will Pay Co up to $950 Mln, Including $600 Mln Upfront Payment","url":"https://stock-news.laohu8.com/highlight/detail?id=2634474263","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634474263?lang=en_us&edition=fundamental","pubTime":"2026-05-12 12:01","pubTimestamp":1778558471,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"b1f4c1fa965d76d4e78087079f689b4e","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260512:nFWN41O1N1:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK0028","LU0267386448.USD","LU1670711123.USD","LU1997245094.SGD","IE00BJT1NW94.SGD","LU2097828714.EUR","LU1323610961.USD","LU0225284248.USD","LU2580892862.HKD","LU0985481810.HKD","LU1868837300.USD","LU0359201612.USD","LU2580892789.USD","BK4007","BK0012","LU0359202008.SGD","IE00BFTCPJ56.SGD","LU1074936037.SGD","LU1655091616.SGD","LU1670711040.USD","LU1868836757.USD","LU0456855351.SGD","LU2097828557.USD","IE00BSNM7G36.USD","LU1883839398.USD","600276","LU0359201885.HKD","LU0321505868.SGD","LU2242646821.SGD","LU0061475181.USD","LU1064131003.USD","01276","LU0405327494.USD","LU1983299246.USD","LU1064130708.USD","LU1989771016.USD","IE0002141913.USD","LU1261432733.SGD","BK4534","LU2133065610.SGD","BK0196","LU1093756325.SGD","LU2360032135.SGD","LU1571399168.USD","BMY","LU2097828805.USD","IE00BFXG1179.USD","LU1997245177.USD","LU1255011170.USD","IE00B2B36J28.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634433263","title":"Jiangsu Hengrui Pharmaceuticals - Deals to Advance Portfolio of 13 Early Stage Programs in Oncology, Hematology and Immunology","url":"https://stock-news.laohu8.com/highlight/detail?id=2634433263","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634433263?lang=en_us&edition=fundamental","pubTime":"2026-05-12 12:01","pubTimestamp":1778558471,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"b1f4c1fa965d76d4e78087079f689b4e","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260512:nFWN41O1N1:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU1997244956.HKD","BK0183","IE00BFXG1179.USD","LU0456855351.SGD","LU2097828631.EUR","LU0882574055.USD","LU2495084118.USD","LU1883839398.USD","LU0237698245.USD","LU2543165471.USD","LU2360032135.SGD","IE00BJT1NW94.SGD","LU0225771236.USD","LU1074936037.SGD","LU1580142542.USD","IE00BJJMRZ35.SGD","BK0060","LU1781817850.SGD","LU2328871848.SGD","LU2242652126.USD","LU1323610961.USD","LU1585245621.USD","LU1571399168.USD","LU2097828474.EUR","LU1064131003.USD","IE0002141913.USD","BK1191","LU1868837300.USD","LU1868836914.USD","LU0096364046.USD","LU0306806265.USD","LU1989771016.USD","LU0321505439.SGD","LU0267386448.USD","LU0432979614.USD","LU2242646821.SGD","IE00B2B36J28.USD","IE00BFTCPJ56.SGD","BK0028","BMY","LU0868494617.USD","LU0114720955.EUR","LU2125154935.USD","BK4007","LU2488822045.USD","LU0359201612.USD","LU0061475181.USD","01276","LU0225284248.USD","600276"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634263442","title":"Hengrui signs global licensing, R&D collaboration pact with Bristol Myers Squibb","url":"https://stock-news.laohu8.com/highlight/detail?id=2634263442","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634263442?lang=en_us&edition=fundamental","pubTime":"2026-05-12 12:00","pubTimestamp":1778558452,"startTime":"0","endTime":"0","summary":"Jiangsu Hengrui Medicine entered global strategic collaboration and licensing deal with Bristol Myers Squibb on May 12, 2026, covering 13 preclinical programs across oncology, hematology, immunology.BMS to pay up to USD 950 million in upfront-related payments, including USD 600 million upfront, USD 175 million first anniversary payment, USD 175 million conditional 2028 anniversary payment.Potential total value up to about USD 15.2 billion tied to option exercises and development, regulatory, commercialization milestones; Hengrui also eligible for tiered royalties on net sales outside mainland China, Hong Kong, Macau.BMS receives exclusive rights outside mainland China, Hong Kong, Macau for Hengrui-originated programs and jointly developed programs; Hengrui receives exclusive rights in those territories for BMS-originated programs.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely in","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"b1f4c1fa965d76d4e78087079f689b4e","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260512:nNDL2dD1Xm:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BJT1NW94.SGD","LU1883839398.USD","600276","LU1093756325.SGD","LU1868836757.USD","LU0432979614.USD","IE0002141913.USD","LU1146622755.USD","LU2097828805.USD","LU0321505439.SGD","IE00BJJMRZ35.SGD","LU1969619763.USD","LU1997244956.HKD","BK4585","BK0183","BK4007","LU1781817850.SGD","LU2242652126.USD","LU2580892789.USD","LU2133065610.SGD","BK0028","LU0225771236.USD","LU0267386448.USD","BK4532","LU2289578879.USD","LU1328615791.USD","LU0061475181.USD","LU2495084118.USD","LU2097828714.EUR","LU0456855351.SGD","LU1074936037.SGD","LU2360032135.SGD","LU0321505868.SGD","BK0012","LU0882574055.USD","BMY","LU1064130708.USD","IE0009355771.USD","LU1718418525.SGD","BK4534","LU1868837300.USD","LU2097828557.USD","LU1323610961.USD","LU1868837136.USD","LU2580892862.HKD","LU2097828631.EUR","IE00BFXG1179.USD","IE00BFTCPJ56.SGD","LU2148510915.USD","LU1430594728.SGD"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"listingDate":"2000-10-18","address":"江苏省连云港市连云区经济技术开发区黄河路38号","stockEarnings":[{"period":"1week","weight":0.0225},{"period":"1month","weight":-0.0648},{"period":"3month","weight":-0.0728},{"period":"6month","weight":-0.1417},{"period":"1year","weight":0.0092},{"period":"ytd","weight":-0.0937}],"companyName":"江苏恒瑞医药股份有限公司","boardCode":"AI0027","perCapita":"13918股","boardName":"医药制造业","registeredCapital":"663719万元","compareEarnings":[{"period":"1week","weight":-0.0107},{"period":"1month","weight":0.0269},{"period":"3month","weight":0.0131},{"period":"6month","weight":0.0363},{"period":"1year","weight":0.2232},{"period":"ytd","weight":0.042}],"survey":"　　江苏恒瑞医药股份有限公司的主营业务是药品的研发、生产和销售。公司的主要产品是马来酸吡咯替尼片、注射用卡瑞利珠单抗、瑞维鲁胺片、海曲泊帕乙醇酰胺片、羟乙磺酸达尔西利片、碘佛醇注射液。自2019年起，公司连续七年跻身美国《制药经理人》(PharmExec)杂志评选的全球制药企业50强榜单。","serverTime":1778962910905,"listedPrice":11.98,"stockholders":"458309人(较上一季度增加1.93%)","compareStock":{"symbol":"000001.SH","name":"SSE Comp"}},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.2","shortVersion":"4.42.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Jiangsu Hengrui Pharmaceuticals Co.,Ltd.(600276),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Jiangsu Hengrui Pharmaceuticals Co.,Ltd.(600276) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Jiangsu Hengrui Pharmaceuticals Co.,Ltd.,600276,Jiangsu Hengrui Pharmaceuticals Co.,Ltd.股票,Jiangsu Hengrui Pharmaceuticals Co.,Ltd.股票老虎,Jiangsu Hengrui Pharmaceuticals Co.,Ltd.股票老虎国际,Jiangsu Hengrui Pharmaceuticals Co.,Ltd.行情,Jiangsu Hengrui Pharmaceuticals Co.,Ltd.股票行情,Jiangsu Hengrui Pharmaceuticals Co.,Ltd.股价,Jiangsu Hengrui Pharmaceuticals Co.,Ltd.股市,Jiangsu Hengrui Pharmaceuticals Co.,Ltd.股票价格,Jiangsu Hengrui Pharmaceuticals Co.,Ltd.股票交易,Jiangsu Hengrui Pharmaceuticals Co.,Ltd.股票购买,Jiangsu Hengrui Pharmaceuticals Co.,Ltd.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Jiangsu Hengrui Pharmaceuticals Co.,Ltd.(600276),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Jiangsu Hengrui Pharmaceuticals Co.,Ltd.(600276) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction